In conclusion, cFAM210A, which is degraded in response to HBx-mediated m6A modification, inhibited tumorigenesis in HCC by suppressing the transactivation function of YBX1 toward MET. The gene discussed is YBX1; the disease is hepatocellular carcinoma.